Dan Siskind

Prof Siskind trained as a psychiatrist in Australia and the United States. He graduated from medicine at the University of Queensland in 1998. After working with Doctors Without Borders in Chechnya in 2000, he became interested in psychiatry. He moved to Boston in 2002, where he did his psychiatry residency at Boston University and a Master of Public Health at Harvard University. He returned to Brisbane in June 2008 as a clinical academic psychiatrist at the Metro South Addiction and Mental Health Service. He completed his Ph.D in Feb 2014. His research interests include clozapine and treatment refractory schizophrenia, the physical health of people with severe and persistent mental illness, supported accommodation, assertive community treatment and mental health services research. He was awarded an NHMRC Investigator Grant as a Leadership Fellow (L1 2027-2031) an Emerging Leadership Fellow (EL2 2021-2025) and an NHMRC Early Career Fellowship (ECF 2016-2019). He has a current CIA MRFF RCRDUN grant looking at treatments to reduce cardiometabolic morbidity among people with schizophrenia. He was the SIRS 2026 Outstanding Clinical and Community Research Award recipient, and was elected to the Australian Academy of Health and Medical Sciences in 2025. He has over 350 peer reviewed publications, including first author in the highly ranked Lancet, World Psychiatry, Lancet Psychiatry, BJPsych, ANZJP, & Schizophrenia Bulletin. He is a named investigator on over $65 million in competitive research grants, with over $9 million as CIA.